BeiGene Ltd Sponsored ADR

Apr 11 6:23am ET Drugmakers look to alternative suppliers after draft U.S. legislation, FT says by TipRanks Apr 08 9:03am ET BeiGene price target lowered to $164.30 from $179.30 at BofA by TipRanks Apr 08 6:04am ET Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE), Alcon (ALC) and Teladoc (TDOC) by TipRanks Mar 27 6:16am ET BeiGene price target lowered to $161 from $196 at Bernstein by TipRanks Mar 26 8:57pm ET BeiGene price target lowered to $161 from $196 at Bernstein by TipRanks Mar 26 7:50pm ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE) and BeiGene (BGNE) by TipRanks Mar 20 4:22pm ET BeiGene Announces Executive Team Reshuffle and Director Pay Revision by TipRanks Mar 15 12:03pm ET JPMorgan biotech/pharma analysts hold an analyst/industry conference call by TipRanks Mar 14 4:28pm ET BeiGene receives FDA approval for Tevimbra by TipRanks Mar 14 2:04pm ET BeiGene gets approval for Tevimbra BLA by TipRanks Mar 13 8:10am ET BeiGene announces first doses of Brukinsa administered by TipRanks Mar 07 5:20pm ET BeiGene announces FDA accelerated approval of BRUKINSA by TipRanks Feb 29 10:02am ET BeiGene announces new efficacy analysis comparing Brukinsa vs. Acalabrutinib by TipRanks Feb 28 12:10am ET Analysts Are Bullish on These Healthcare Stocks: Athira Pharma (ATHA), BeiGene (BGNE) by TipRanks Feb 27 11:45pm ET Buy Rating Reaffirmed on BeiGene Amid Strong Brukinsa Sales and Strategic Stability by TipRanks Feb 27 7:41am ET BeiGene price target lowered to $345 from $350 at Guggenheim by TipRanks Feb 27 7:25am ET BeiGene price target raised to $235 from $224 at TD Cowen by TipRanks Feb 27 7:18am ET BeiGene Hold Rating Upheld Amid Revenue Growth and Market Challenges by TipRanks Feb 27 6:19am ET BeiGene’s Biologics License Application for tevimbra accepted by FDA by TipRanks Feb 27 2:25am ET BeiGene: Balancing Robust Zanubrutinib Sales and Financial Challenges – A Hold Rating by TipRanks Feb 27 1:04am ET BeiGene, Ltd.’s New Technology Risk – A Cause for Worry? by TipRanks Feb 26 4:45pm ET Brukinsa’s Market Dominance and BeiGene’s Promising Pipeline Fuel Buy Rating and New Price Target by TipRanks Feb 26 7:20am ET Analysts Are Bullish on Top Healthcare Stocks: BeiGene (BGNE), McKesson (MCK) by TipRanks Feb 26 6:05am ET BeiGene reports Q4 EPS ($3.53), consensus ($3.73) by TipRanks Feb 26 5:12am ET BeiGene receives CHMP opinion recommending approval of tislelizumab by TipRanks Feb 19 6:16am ET BeiGene price target lowered to $163 from $200 at BofA by TipRanks Feb 19 5:45am ET BeiGene Hold Rating Maintained Amid Mixed Drug Sales and Revised Financial Risk Profile by TipRanks Feb 12 8:20am ET Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), BeiGene (BGNE) and Catalent (CTLT) by TipRanks Feb 06 7:04am ET BeiGene assumed with an Overweight at JPMorgan by TipRanks Feb 05 10:51am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Feb 02 9:27am ET BeiGene announces Ontario, Quebec publicly list Brukinsa to treat CLL by TipRanks